Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, and sells in vitro diagnostic reagents and instruments, and vaccines in China and internationally. It operates through Diagnostics Division and Vaccine Division segments. The company offers chemiluminescence detection, biochemical, hepatitis B core antibody detection, and HIV reagents; rapid urine tests for hepa… Read more
Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392) - Net Assets
Latest net assets as of September 2025: CN¥12.27 Billion CNY
Based on the latest financial reports, Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392) has net assets worth CN¥12.27 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥14.37 Billion) and total liabilities (CN¥2.10 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥12.27 Billion |
| % of Total Assets | 85.4% |
| Annual Growth Rate | 37.26% |
| 5-Year Change | 382.41% |
| 10-Year Change | 1622.45% |
| Growth Volatility | 49.24 |
Beijing Wantai Biological Pharmacy Enterprise Co Ltd - Net Assets Trend (2013–2024)
This chart illustrates how Beijing Wantai Biological Pharmacy Enterprise Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Beijing Wantai Biological Pharmacy Enterprise Co Ltd (2013–2024)
The table below shows the annual net assets of Beijing Wantai Biological Pharmacy Enterprise Co Ltd from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥12.45 Billion | -3.38% |
| 2023-12-31 | CN¥12.88 Billion | +2.54% |
| 2022-12-31 | CN¥12.56 Billion | +175.40% |
| 2021-12-31 | CN¥4.56 Billion | +76.81% |
| 2020-12-31 | CN¥2.58 Billion | +63.24% |
| 2019-12-31 | CN¥1.58 Billion | +15.35% |
| 2018-12-31 | CN¥1.37 Billion | +52.44% |
| 2017-12-31 | CN¥898.99 Million | -6.33% |
| 2016-12-31 | CN¥959.70 Million | +32.80% |
| 2015-12-31 | CN¥722.69 Million | +24.53% |
| 2014-12-31 | CN¥580.32 Million | +51.89% |
| 2013-12-31 | CN¥382.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Beijing Wantai Biological Pharmacy Enterprise Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3182.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥7.23 Billion | 58.97% |
| Common Stock | CN¥1.27 Billion | 10.32% |
| Other Components | CN¥3.77 Billion | 30.71% |
| Total Equity | CN¥12.26 Billion | 100.00% |
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Competitors by Market Cap
The table below lists competitors of Beijing Wantai Biological Pharmacy Enterprise Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Betsson AB (publ)
PINK:BTSNY
|
$1.39 Billion |
|
Jereissati Participações S.A.
SA:IGTI11
|
$1.39 Billion |
|
Ryman Healthcare Limited
PINK:RHCGF
|
$1.39 Billion |
|
Acadian Asset Management Inc
NYSE:AAMI
|
$1.39 Billion |
|
Borregaard ASA
PINK:BRRDF
|
$1.39 Billion |
|
Hakuhodo DY Holdings Inc
OTCGREY:HKUOF
|
$1.39 Billion |
|
Jonjee Hi-tech Industrial and Commercial Holding Co Ltd
SHG:600872
|
$1.39 Billion |
|
Betta Pharmaceuticals Co Ltd
SHE:300558
|
$1.39 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Beijing Wantai Biological Pharmacy Enterprise Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 12,700,598,000 to 12,262,802,018, a change of -437,795,982 (-3.4%).
- Net income of 106,235,425 contributed positively to equity growth.
- Dividend payments of 410,180,871 reduced retained earnings.
- Share repurchases of 184,443,196 reduced equity.
- Other comprehensive income decreased equity by 696,604,229.
- Other factors increased equity by 747,196,889.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥106.24 Million | +0.87% |
| Dividends Paid | CN¥410.18 Million | -3.34% |
| Share Repurchases | CN¥184.44 Million | -1.5% |
| Other Comprehensive Income | CN¥-696.60 Million | -5.68% |
| Other Changes | CN¥747.20 Million | +6.09% |
| Total Change | CN¥- | -3.45% |
Book Value vs Market Value Analysis
This analysis compares Beijing Wantai Biological Pharmacy Enterprise Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.30x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 102.66x to 4.30x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥0.39 | CN¥39.75 | x |
| 2014-12-31 | CN¥0.57 | CN¥39.75 | x |
| 2015-12-31 | CN¥0.67 | CN¥39.75 | x |
| 2016-12-31 | CN¥0.87 | CN¥39.75 | x |
| 2017-12-31 | CN¥0.86 | CN¥39.75 | x |
| 2018-12-31 | CN¥1.26 | CN¥39.75 | x |
| 2019-12-31 | CN¥1.42 | CN¥39.75 | x |
| 2020-12-31 | CN¥2.14 | CN¥39.75 | x |
| 2021-12-31 | CN¥3.63 | CN¥39.75 | x |
| 2022-12-31 | CN¥9.88 | CN¥39.75 | x |
| 2023-12-31 | CN¥10.08 | CN¥39.75 | x |
| 2024-12-31 | CN¥9.23 | CN¥39.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Beijing Wantai Biological Pharmacy Enterprise Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.87%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.73%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 1.20x
- Recent ROE (0.87%) is below the historical average (20.70%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 20.89% | 16.00% | 0.82x | 1.59x | CN¥41.62 Million |
| 2014 | 20.41% | 19.87% | 0.74x | 1.39x | CN¥60.43 Million |
| 2015 | 17.30% | 17.53% | 0.62x | 1.60x | CN¥50.37 Million |
| 2016 | 16.67% | 17.56% | 0.58x | 1.64x | CN¥59.28 Million |
| 2017 | 17.12% | 15.84% | 0.57x | 1.89x | CN¥62.57 Million |
| 2018 | 21.71% | 29.82% | 0.54x | 1.34x | CN¥158.07 Million |
| 2019 | 13.40% | 17.64% | 0.55x | 1.39x | CN¥52.98 Million |
| 2020 | 26.51% | 28.76% | 0.67x | 1.37x | CN¥421.63 Million |
| 2021 | 45.26% | 35.15% | 0.82x | 1.58x | CN¥1.57 Billion |
| 2022 | 38.37% | 42.34% | 0.69x | 1.32x | CN¥3.50 Billion |
| 2023 | 9.82% | 22.64% | 0.35x | 1.24x | CN¥-22.38 Million |
| 2024 | 0.87% | 4.73% | 0.15x | 1.20x | CN¥-1.12 Billion |
Industry Comparison
This section compares Beijing Wantai Biological Pharmacy Enterprise Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392) | CN¥12.27 Billion | 20.89% | 0.17x | $1.39 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |